TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Argent Biopharma ( (AU:RGT) ) is now available.
Argent BioPharma has announced the issuance of 2,252,381 fully paid ordinary shares, which are exempt from certain disclosure requirements under the Corporations Act 2001. This move aligns with the company’s compliance with regulatory provisions, ensuring transparency and informed investor decisions. The issuance is part of Argent BioPharma’s strategy to advance its clinical programs and strengthen its market position in addressing urgent medical needs.
More about Argent Biopharma
Argent BioPharma Ltd. (ASX: RGT) is a clinical-stage biopharmaceutical company focused on developing nano-engineered medicines that address the balance between the nervous and immune systems. The company’s lead candidates, CannEpil® and CimetrA®, are designed to treat drug-resistant epilepsy and cytokine-driven inflammatory and autoimmune disorders, respectively. Argent BioPharma utilizes proprietary delivery platforms to enhance drug efficacy and protection, with a focus on unmet needs in central nervous system and systemic inflammation.
Average Trading Volume: 98,425
Technical Sentiment Signal: Sell
Current Market Cap: A$8.68M
See more data about RGT stock on TipRanks’ Stock Analysis page.